Table 4.

Clinical characteristics of Medication (MED) compared to No Medication (NO MED) groups at remission start.

MED, n = 34 (%)NO MED, n = 38 (%)p
Sex (F)33 (97.1)32 (84.2)0.11
Age at diagnosis, yrs27.9 ± 11.736.1 ± 15.20.01
Length of followup at remission onset, yrs9.13 ± 8.749.13 ± 8.791.00
Race
  White25 (73.5)32 (84.2)
  Black4 (11.8)0 (0)0.27 (white vs all others)
  Asian4 (11.8)2 (5.3)
  Other1 (2.9)4 (10.5)
SLEDAI-2K at first clinic visit8.15 ± 7.728.03 ± 9.470.95
AMS (from clinic entry to remission onset)4.24 ± 2.673.02 ± 1.930.03
Damage Index*
  Score > 018/31 (58.1)20/37 (54.1)
  Mean score1.68 ± 1.871.08 ± 1.320.14
Organ system involvement (ever), by SLEDAI-2K, from clinic entry to remission onset
  Musculoskeletal11 (32.4)16 (42.1)0.39
  Skin28 (82.4)28 (73.7)0.38
  Vasculitis6 (17.7)10 (26.3)0.38
  Renal19 (55.9)26 (68.4)0.27
  Central nervous system18 (52.9)14 (36.8)0.17
  Cardiac – SLE-related9 (26.5)12 (31.6)0.63
  Cardiac – atherosclerotic*4 (11.8)4 (10.5)1.00
  Thrombotic*4/28 (14.3)3/25 (12.0)1.00
  Pulmonary*10 (29.4)5 (13.2)0.09
  • * Diagnosed clinically and/or radiographically, not a component of SLEDAI-2K. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; AMS: adjusted mean SLEDAI; SLICC: Systemic Lupus International Collaborating Clinics; SLE: systemic lupus erythematosus.